Hearing profile in hepatitis C virus patients under dual treatment with interferon and ribavirin

References

• Strickland GT, Elhefni H, Salman T, Waked I, Abdel Hamid M, Mikhail NN, . Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg. 2002;67:436–42.
   PubMed Web of Science ®Google Scholar
• Abe S, Narita R, Oto T, Tabaru A, Otsuki M. Effect of combination therapy with ribavirin and high-dose interferon-a 2b for 24 weeks in chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:308–12.
   PubMedGoogle Scholar
• Chung A, Older SA. Interferon-alpha associated arthritis. J Rheumatol. 1997;24:1844–5.
   PubMed Web of Science ®Google Scholar
• Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, . Sudden hearing loss associated with peg interferon and ribavirin combination therapy during hepatitis C treatment World J Gastroenterol. 2007;13:5411–2.
   Google Scholar
• Kanda Y, Shigeno K, Matsuo H, Yano M, Yamada N, Kumagami H. Interferon induced hearing loss. Audiology. 1995;34:98–102.
   PubMedGoogle Scholar
• Görür K, , Kandemir ÖÜnal M, Özcan, C. The effect of recombinant interferon-alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx. 2003;30:41–4.
   PubMedGoogle Scholar
• Toosi MN, Hassanabadi MS. Hearing loss as a complication of peginterferon-alpha 2a combination therapy in a patient with hepatitis C virus infection. Hepatitis Monthly. 2004;4:79–82.
   Google Scholar
• Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda Steindl P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol. 2004;99:873–7.
   PubMed Web of Science ®Google Scholar
• Wong VK, Cheong Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. World J Gastroenterol. 2005;11:5392–3.
   PubMed Web of Science ®Google Scholar
• Piekarska A, Jozefowicz Korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol. 2007;46:345–50.
   PubMed Web of Science ®Google Scholar
• Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, . Side-effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–91.
   PubMed Web of Science ®Google Scholar
• Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, Douniadakis D. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity in children. Int J Pediat Otorhinolaryngol. 1999;50:177–84.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus (HCV) RNA quantification. Hepatology. 2000;32:654–9.
   PubMed Web of Science ®Google Scholar
• Saldanha J, Heath A and the WHO Collaborative Study Group. Collaborative study to calibrate hepatitis C virus genotypes 2–6 against the HCV International Standard, 96/790 (genotype 1). Vox Sanguinis. 2003;84:20–7.
   PubMedGoogle Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD Practice Guidelines: Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology. 2009;49:1335–74.
   PubMed Web of Science ®Google Scholar
• Clark JG. Uses and abuses of hearing loss classification. ASHA. 1981;23:493–500.
   PubMedGoogle Scholar
• Soliman SM. Speech discrimination audiometry using Arabic phonetically-balanced words. Ain Shams Med J. 1976; 27:27–30.
   Google Scholar
• Soliman SM, Fathalla A, Shehata M. Development of Arabic staggered spondee words. (SSW) test: In: Proceedings of 8th Ain Shams Med Congress. 1985;2:1220–46.
   Google Scholar
• Kemp D. Otoacoustic emissions, travelling waves and cochlear mechanisms. Hear Res. 1986;22:95–104.
   PubMed Web of Science ®Google Scholar
• Fried MW. Side-effects of therapy of hepatitis C and their management. Hepatology. 2002;36 (Suppl 1):S237–44.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. New Engl J Med. 2006;7:2444–51.
   Google Scholar
• Cadoni G, Marinelli L, de Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus positive on therapy with interferon-alpha: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol. 1998; 112:962–3.
   PubMed Web of Science ®Google Scholar
• Tunca A, Erbaykak M, Ayta Ş, T-Rkay C. Axonal neuropathy and hearing loss associated with interferon-alpha treatment in chronic hepatitis B: a case report. Turk J Gastroenterol. 2004;15:97–9.
   PubMedGoogle Scholar
• Cole RR, Jahrsdoerfer RA. Sudden hearing loss: an update. Am J Otol. 1988;9:211–5.
   PubMedGoogle Scholar
• Stübgen, JP. Interferon-alpha and neuromuscular disorders. J Neuroimmunol. 2009;207:3–17.
   PubMedGoogle Scholar
• Guneri EA, Serbeteioglu B, Ikiz AO, Guneri A, Ceryan K. Transient evoked otoacoustic emissions monitoring of cisplatin induced ototoxicity in guinea pigs: the protective effect of vitamin B treatment . Auris Nasus Larynx. 2001; 28:9–14.
   PubMed Web of Science ®Google Scholar
• Akyol MU, Sarac S, Akyol G, Atac A, Poyraz A, Belgin E, . Investigation of the ototoxic effects of interferon-alpha 2A on the mouse cochlea. Otolaryngol Head and Neck Surg. 2001;124:107–10.
   PubMed Web of Science ®Google Scholar
• Jung TTK, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, non-steroidal anti-inflammatory drugs, and quinine. Otol Clin North Am. 1993;26:791–810.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Shigeno K, Kinoshita N, Nakao K, Matsuo H. Sudden hearing loss associated with interferon. Lancet. 1994; 343:1134–5.
   PubMed Web of Science ®Google Scholar